The invention is based on the fact that if the pH in the stomach of a human being is between 1 and 2, the digestion of the proteins takes place as a result of the action of the digestive enzyme pepsin. In the case of interdigestive acidity, the pepsin acts on the walls of the stomach, first causing gastritis, and then gastric and duodenal ulcers. The action of the medicaments, ranitidine and omeprazol, on said acidity inhibits the natural production of hydrochloric acid or causes diarrheoa due t...

PROBLEM TO BE SOLVED: To provide a solid pharmaceutical formulation containing ranitidine that controls discoloration of the ranitidine, and a method for producing a ranitidine-supporting particle to be blended with the formulation. ; SOLUTION: The solid pharmaceutical formulation containing ranitidine is characterized in that it has acid-controlling power larger than 200 mL which is determined by the acid-controlling power testing method according to the fifteenth Revision of Japanese Pharmacop...

The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP) in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia in particular caused by brain injury more in particular caused by traumatic (TBI) and non-traumatic brain injury.In particular the histamine antagonist is selected from the group of acrivastine alimemazine antazoline astemizole azatadine azelastine bromphenirami...

An encapsulate comprises an outer shell and an inner core, the inner core comprising an ingredient selected from plant sterol compounds such as phytosterols and/or phytostanols and/or their esters, and at least one, preferably at least two, of the following groups: a, b, c, d, e, f, g, h, i, j, k. a) Amino acids